Clinical Observation of Oxcarbazepine on the Children with Epilepsy

吴洁,宋小青,王廉文,蔡嘉琳,葛欣,鲍为群

DOI: https://doi.org/10.3969/j.issn.1005-2224.2008.01.014

2008-01-01

Abstract:Objective To evaluate the efficacy and safety of oxcarbazepine (OXC) in the treatment of the childhood partial seizure (PS) or intractable Epilepsy(IE).Methods 52 patients were divided into two groups.37 newly diagnosed patients who had never accepted standard therapy entered mono-therapy group,and 15 patients who have had more than two anti-epileptic drugs(AEDs) regularity with uncontrol served as add-on therapy group.The initial dose was 5~10 mg/(kg·d),every 5 to 7 days the dose was increased 5~10mg / mg/(kg·d),and the maintenance dose was 20~40 mg/(kg·d),( given twice per day).With the open-label auto-control method,we follow up the efficacy,the tolerability and the safety of OXC during the 6 months to 2 years of the treatment both in the monothrapy group and the add-on therapy group,and we analyze the relationship of the efficacy according the dosage and the age.Results The effective rate and the withdraw rate were 86.48% and 2.7%,respectively,25 of 37(67.56%) patients achieved seiz seizure-free in monotherapy group.In add on therapy group,the effective and withdraw rate were 46.67% and 26.67%,respectively,2 of 15(13.00%) patients achieved seizure free.5 patients exited,4 patients because of uncomplete seizure control and 1 patient because of skin rash.The mean dose in the 4 year group was significantly higher compared with the older age groups (P=0.03).In the group which seizure was reduced≥50% required a significantly higher mean dose compared to the group which seizure was reduced 50%(P=0.029).Ten patients (21.15%) reported adverse events,such as drowsiness,dizziness,rash.For the most part,these adverse events tended to be transient.No hyponatremia was observed.Conclusion These findings suggest that OXC monotherapy is significantly effective in children with PS.And partly effective in IE.It is well tolerated,safety,and the adverse events is transient dose-dependent.